Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA approves Baxter’s IV insulin Myxredlin
Myxredlin is claimed to be the first and only ready-to-use insulin for intravenous (IV) infusion in the hospital and other acute care settings. It is provided with an
Myxredlin is claimed to be the first and only ready-to-use insulin for intravenous (IV) infusion in the hospital and other acute care settings. It is provided with an
Multiple sclerosis (MS) is categorized as rare disease in China with an estimated 30,000 MS patients in China. Gilenya is the 3rd most prescribed MS disease modifying treatment
Otezla (apremilast) 30mg is an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4), particularly for cyclic adenosine monophosphate (cAMP). It is claimed to be the first and only approved
TG6002 is a next-generation oncolytic virus (OV), which has multiple mechanisms of action. It has been engineered to combine the killing of cancer cells (oncolysis), the production of
“We are very pleased to have received the rare pediatric disease designation for LM-030 which has demonstrated safety and clinical efficacy in a Phase I/II study. Netherton Syndrome
The BBT-877 is Bridge Biotherapeutics’ autotaxin inhibitor being developed to treat various fibrosing interstitial lung diseases, including idiopathic pulmonary fibrosis (IPF). Under the deal, Bridge Biotherapeutics will secure
In preclinical studies, the oral, small molecule candidate, LYT-100, demonstrated anti-fibrotic and anti-inflammatory mechanisms, and in a Phase 1 clinical trial in healthy volunteers, LYT-100 was observed to
The FDA has approved Recarbrio to treat patients 18 years of age and older who have limited or no alternative treatment options for cUTI, including pyelonephritis, caused by
DCR-PHXC is the only RNAi investigational therapy in development for the treatment of all types of PH, a family of severe, rare, inherited disorders of the liver that
The deal includes an upfront payment, and contingent clinical, development and regulatory milestone payments. AMAL Therapeutics is also eligible to receive up to €100m (£89.8m) based on the